论文部分内容阅读
目的探讨超敏C反应蛋白(hsCRP)水平与无保护左主干冠状动脉(ULMCA)病变行经皮冠状动脉介入治疗(PCI)术后再狭窄的关系。方法76例ULMCA病变患者常规行冠状动脉造影(CAG)及支架置入,术前测定外周血hsCRP并依其水平分组,术后随访观察临床主要不良心血管事件(MACE)和CAG再狭窄发生率。结果术前外周血hsCRP水平正常(<3.0mg/L)组22例,术后再狭窄发生率6.7%(1/15);hsCRP升高(3.0～3.9mg/L)组33例,术后再狭窄发生率11.1%(2/18);hsCRP明显升高(≥4.0mg/L)组21例,术后再狭窄发生率30.0%(6/21)。组间比较,P>0.05。结论冠脉再狭窄发生率有随术前hsCRP升高而增加的趋势。
Objective To investigate the relationship between the level of hsCRP and restenosis after percutaneous coronary intervention (PCI) in unprotected left main coronary artery (ULMCA). Methods Sixty-six patients with ULMCA lesions underwent routine coronary angiography (CAG) and stent implantation. The peripheral blood hsCRP levels were measured before surgery and were grouped according to their level. The incidence of major adverse cardiovascular events (MACE) and CAG restenosis . Results Twenty-two patients had normal hsCRP levels (<3.0mg / L) and 6.7% (1/15) had postoperative restenosis; 33 patients had hsCRP elevated (3.0-3.9mg / L) The incidence of restenosis was 11.1% (2/18). There were 21 cases with hsCRP increased significantly (≥4.0 mg / L). The incidence of restenosis was 30.0% (6/21). Between groups, P> 0.05. Conclusion The incidence of coronary artery stenosis increases with the increase of hsCRP before surgery.